Agenus (NASDAQ:AGEN) Share Price Passes Above 200-Day Moving Average – Should You Sell?

Agenus Inc. (NASDAQ:AGEN) passed above its 200-day moving average during trading on Monday . The stock has a 200-day moving average of $2.87 and traded as high as $3.84. Agenus shares last traded at $3.82, with a volume of 422,744 shares.

Wall Street Analyst Weigh In

AGEN has been the topic of a number of research analyst reports. Wall Street Zen upgraded Agenus from a “strong sell” rating to a “hold” rating in a research note on Thursday, May 22nd. Robert W. Baird boosted their target price on Agenus from $3.00 to $4.00 and gave the stock a “neutral” rating in a research note on Tuesday, May 13th. HC Wainwright restated a “neutral” rating on shares of Agenus in a research note on Tuesday, May 13th. Finally, B. Riley restated a “buy” rating on shares of Agenus in a research note on Monday, April 21st. Six equities research analysts have rated the stock with a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $9.00.

Agenus Stock Up 0.8%

The firm has a 50 day moving average of $2.48 and a 200 day moving average of $2.87. The firm has a market cap of $104.73 million, a PE ratio of -0.34 and a beta of 1.48.

Agenus (NASDAQ:AGEN) last posted its quarterly earnings data on Monday, May 12th. The biotechnology company reported ($1.03) EPS for the quarter, beating the consensus estimate of ($1.61) by $0.58. The firm had revenue of $24.07 million during the quarter, compared to analysts’ expectations of $26.38 million. On average, research analysts anticipate that Agenus Inc. will post -12.55 EPS for the current year.

Hedge Funds Weigh In On Agenus

Several institutional investors have recently bought and sold shares of the company. Barclays PLC lifted its stake in Agenus by 17.7% in the fourth quarter. Barclays PLC now owns 32,737 shares of the biotechnology company’s stock valued at $90,000 after purchasing an additional 4,924 shares during the last quarter. Apollon Wealth Management LLC raised its holdings in Agenus by 25.0% during the 1st quarter. Apollon Wealth Management LLC now owns 25,007 shares of the biotechnology company’s stock valued at $38,000 after acquiring an additional 5,000 shares during the period. Corton Capital Inc. bought a new stake in Agenus during the 4th quarter valued at $36,000. Charles Schwab Investment Management Inc. raised its holdings in Agenus by 32.8% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 63,685 shares of the biotechnology company’s stock valued at $96,000 after acquiring an additional 15,731 shares during the period. Finally, Virtu Financial LLC bought a new stake in Agenus during the 4th quarter valued at $51,000. Hedge funds and other institutional investors own 61.46% of the company’s stock.

Agenus Company Profile

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.